Merrill Lynch initiates Human Genome at neutral

Human Genome Sciences Inc. coverage was initiated by Merrill Lynch analyst Hari Sambasivam with a neutral rating. Positives for the company include phase II trials of Lymphostate-B for B-cell disorders, Albuferon for hepatitis C and TRAIL antibodies for cancers, large underserved markets and a partnership with GlaxoSmithKline. Shares of the Rockville, Md.-based biopharmaceutical company were down $0.28, or 3.38%, at $8.01 on volume of 3,059,458 shares versus the three-month running average of 3,725,880 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.